GGrantIndex
Sort

16,300 grants matching fatty liver disease

Development of ferroptosis inhibitors for Huntington Disease

$389,574
Brent R Stockwell · Columbia Univ New York Morningside · R33 · FY2021 · NS

Metabolism of the VLDL receptor and ApoE receptor 2

$389,550
Joachim J Herz · Ut Southwestern Medical Center · R37 · FY2014 · HL

Role of heat shock protein 90 in alcoholic liver disease

$389,500
Pranoti Mandrekar · Univ Of Massachusetts Med Sch Worcester · R01 · FY2009 · AA

Elucidating Vascular Neuropilin 1 (NRP1) Functions in Response to Novel Interactions with Insulin Substrates

$389,479
Ye Ding · Georgia State University · R01 · FY2021 · HL

Optimized Metabolite Extraction, Separation, and Identification for Metabolomics

$389,426
Andrew Patterson · Pennsylvania State University, The · R01 · FY2015 · ES

Lipid Binding Proteins in Obesity and Diabetes Syndromes

$389,372
David A Bernlohr · University Of Minnesota · R01 · FY2020 · DK

Lipid Binding Proteins in Obesity and Diabetes Syndromes

$389,372
David A Bernlohr · University Of Minnesota · R01 · FY2019 · DK

Modified Intestinal apoAI-particles and Lymphatics Accelerate CKD-driven CVD

$389,250
Valentina Kon · Vanderbilt University Medical Center · P01 · FY2024 · HL

The Role of Bacterial Choline Metabolism in Host Stress Responses

$389,246
Jonathan Mark Brown · Cleveland Clinic Lerner Com-Cwru · R01 · FY2019 · DK

Modeling the Disease Burden and Cost-Effectiveness of Screening and Treatment for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Patients

$389,221
Michael B Rothberg · Cleveland Clinic Foundation · R01 · FY2022 · HS

Heat shock protein 90 in alcoholic liver disease: targeting macrophage function

$389,200
Pranoti Mandrekar · Univ Of Massachusetts Med Sch Worcester · R01 · FY2015 · AA

Role of SH2-B in Glucose Metabolism

$389,129
Liangyou Rui · University Of Michigan At Ann Arbor · R01 · FY2009 · DK

Modeling the Disease Burden and Cost-Effectiveness of Screening and Treatment for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Patients

$389,092
Michael B Rothberg · Cleveland Clinic Foundation · R01 · FY2021 · HS

Metabolic vulnerability due to dysregulated lipid metabolism in PDAC cachexia

$389,052
Aaron Grossberg · Oregon Health & Science University · R37 · FY2023 · CA

Development of delivery methods for combination microRNA treatment of alcohol-associated liver disease

$389,037
David Oupicky · University Of Nebraska Medical Center · R01 · FY2019 · AA

Development of delivery methods for combination microRNA treatment of alcohol-associated liver disease

$389,037
David Oupicky · University Of Nebraska Medical Center · R01 · FY2022 · AA

Development of delivery methods for combination microRNA treatment of alcohol-associated liver disease

$389,037
David Oupicky · University Of Nebraska Medical Center · R01 · FY2021 · AA

Development of delivery methods for combination microRNA treatment of alcohol-associated liver disease

$389,037
David Oupicky · University Of Nebraska Medical Center · R01 · FY2020 · AA

Development of delivery methods for combination microRNA treatment of alcohol-associated liver disease

$389,037
David Oupicky · University Of Nebraska Medical Center · R01 · FY2023 · AA

Elucidating the Role and Regulation of Proteostasis in Hepatic Fibrogenesis

$389,028
Jessica L Maiers · Indiana University Indianapolis · R01 · FY2025 · DK

Lipotoxicity in Alcoholic Liver Disease

$388,951
Zhanxiang Zhou · University Of North Carolina Greensboro · R01 · FY2015 · AA

Molecular Pharmacology of Insulin Resistance in Burns

$388,933
Jeevendra Martyn · Massachusetts General Hospital · R01 · FY2010 · GM

Molecular basis of fatty acid transport by peroxisomal ABC transporters

$388,933
Amer Alam · University Of Minnesota · R01 · FY2022 · GM

Hepatitis B Clinical Research Network

$388,900
Arun J Sanyal · Virginia Commonwealth University · U01 · FY2009 · DK

Physiology, pathology and animal core

$388,881
Richard C Davis · University Of California Los Angeles · P01 · FY2015 · HL